Cargando…

Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xinxin, Wang, Ning, Fu, Peng, An, Yanliang, Sun, Fangfang, Wang, Chengdong, Han, Xiao, Zhang, Yunlong, Yu, Xiaohong, Liu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Cardiovascular Pharmacology 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635406/ https://www.ncbi.nlm.nih.gov/pubmed/37643027 http://dx.doi.org/10.1097/FJC.0000000000001474

Ejemplares similares

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
por: Zhang, Nannan, et al.
Publicado: (2019)

Effects of rhythm control on left atrial structure remodeling in atrial fibrillation and heart failure with preserved ejection fraction
por: Bai, Lin, et al.
Publicado: (2023)

Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [(18)F]AlF-NOTA-FAPI-04 PET/CT Imaging
por: Sun, Fangfang, et al.
Publicado: (2023)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction
por: Sun, Yuxi, et al.
Publicado: (2023)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Epigenetic remodeling in heart failure with preserved ejection fraction
por: Ambrosini, Samuele, et al.
Publicado: (2022)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Reverse electrical remodeling in rats with heart failure and preserved ejection fraction
por: Cho, Jae Hyung, et al.
Publicado: (2023)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction
por: Sun, Yuxi, et al.
Publicado: (2021)

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
por: Stencel, Jason, et al.
Publicado: (2023)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023)

The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction
por: Franssen, C., et al.
Publicado: (2016)

β-Hydroxybutyrate Mitigated Heart Failure with Preserved Ejection Fraction by Increasing Treg Cells via Nox2/GSK-3β
por: Liao, Shengen, et al.
Publicado: (2021)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2021)

Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study
por: Cortés, Marcelino, et al.
Publicado: (2023)

Cardiac steatosis and left ventricular remodeling in heart failure with reduced and preserved ejection fraction
por: Mahmod, Masliza, et al.
Publicado: (2015)

Morphometric, Hemodynamic, and Multi-Omics Analyses in Heart Failure Rats with Preserved Ejection Fraction
por: Zhang, Wenxi, et al.
Publicado: (2020)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Cardiac Rehabilitation Increases SIRT1 Activity and β-Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection Fraction
por: Corbi, Graziamaria, et al.
Publicado: (2019)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction
por: Hohendanner, Felix, et al.
Publicado: (2018)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02q6htiimuoho2a3nqu4q1pjth